Kazia Therapeutics Ltd (ASX:KZA) Insider Acquires A$19,860.00 in Stock

Kazia Therapeutics Ltd (ASX:KZA) insider Steven Coffey bought 60,000 shares of the company’s stock in a transaction dated Wednesday, July 3rd. The shares were acquired at an average price of A$0.33 ($0.23) per share, for a total transaction of A$19,860.00 ($14,085.11).

ASX:KZA opened at A$0.41 ($0.29) on Friday. Kazia Therapeutics Ltd has a 52 week low of A$0.32 ($0.23) and a 52 week high of A$0.60 ($0.43). The firm has a market cap of $19.61 million and a PE ratio of -1.64. The company’s 50-day simple moving average is A$0.39.

About Kazia Therapeutics

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops therapies for a range of oncology indications. Its lead product is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway that is in Phase II clinical trials to treat glioblastoma multiforme. The company is also developing TRX-E-002-1 (Cantrixil), a third-generation benzopyran molecule, which is in Phase I clinical trials to treat ovarian cancer.

Featured Article: Asset Allocation

Receive News & Ratings for Kazia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kazia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit